Cervical cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A primary or metastatic malignant neoplasm involving the cervix.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Cervical cancer
- Therapeutic area
- Oncology
- cervical cancer
- cervical neoplasm
- tumor of the cervix uteri
- tumour of the cervix uteri
- uterine cervical neoplasm
- cancer of uterine cervix
- cervical cancer, somatic
- malignant cervical neoplasm
- malignant cervical tumor
- malignant cervical tumour
- malignant cervix neoplasm
- malignant cervix tumor
- malignant cervix tumour
- malignant cervix uteri neoplasm
- malignant cervix uteri tumor
- malignant cervix uteri tumour
- malignant neoplasm of cervix
- malignant neoplasm of cervix uteri
- malignant neoplasm of the cervix
- malignant neoplasm of the cervix uteri
- malignant neoplasm of the uterine cervix
- malignant neoplasm of uterine cervix
- malignant tumor of cervix
- malignant tumor of cervix uteri
- malignant tumor of the cervix
And 13 more, listed on the interactive page.
- Severity
- Severe
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0002974
- Parent condition
- MONDO:0002715
Related records
Broader conditions (19)
- Cancer
- Cancer or benign tumor
- Cervix disorder
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Female reproductive organ cancer
- Female reproductive system disorder
- Female reproductive system neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
- Tumor of uterus
- Uterine cancer
- Uterine cervix neoplasm
- Uterine disorder
Narrower conditions (52)
- Cervical adenocarcinoma
- Cervical adenoid basal carcinoma
- Cervical adenoid cystic carcinoma
- Cervical adenosarcoma
- Cervical adenosquamous carcinoma
- Cervical adenosquamous carcinoma, glassy cell variant
- Cervical alveolar soft part sarcoma
- Cervical basaloid carcinoma
- Cervical carcinoma
- Cervical carcinosarcoma
- Cervical clear cell adenocarcinoma
- Cervical endometrioid adenocarcinoma
- Cervical keratinizing squamous cell carcinoma
- Cervical large cell neuroendocrine carcinoma
- Cervical lymphoepithelioma-like carcinoma
- Cervical mucinous adenocarcinoma
- Cervical mucinous adenocarcinoma, minimal deviation variant
- Cervical non-keratinizing squamous cell carcinoma
- Cervical serous adenocarcinoma
- Cervical small cell carcinoma
Trials (2,276)
- [177Lu]Lu-AKIR001 First-in-human Study
- [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
- 1:1 Comparison of the Pocket Colposcope in Kenya
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 2-stage Cervical Cancer Screening in Botswana
- 2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
- 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy
- 4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery
- 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
- A Cervical Cancer Prevention Program in Kenya
- A Chatbot Intervention for Reducing HPV Vaccine Hesitancy
- A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma
Approved drugs (3)
- Bevacizumab
- Tisotumab vedotin
- Topotecan hydrochloride
Drugs in development (147)
- Abipapogene suvaplasmid Phase 2
- Adavosertib Phase 1
- Adebrelimab Phase 2
- Amifostine Phase 2
- APL-501 Phase 2
- Arsenic trioxide Phase 2
- Arundine Phase 3
- Ascorbic acid Phase 2
- Aspirin Phase 2
- Atezolizumab Phase 3
- Atsm copper (II) Phase 2
- Balstilimab Phase 3
- Belotecan Phase 2
- Benmelstobart Phase 2
- Bintrafusp alfa Phase 2
- Bleomycin sulfate Phase 3
- Bortezomib D-mannitol Phase 2
- Bosutinib Phase 1
- Brivanib Phase 2
- Bryostatin 1 Phase 2
Other linked drugs (9)
- Abobotulinumtoxina
- Acetic acid
- Alendronic acid
- Amolimogene bepiplasmid
- Disitamab
- Incobotulinumtoxina
- Indocyanine green
- Misoprostol
- Propranolol